Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Alcohol Use Disorder (AUD)
Interventions: Tirzepatide, Placebo, [11C]raclopride plus drug, [11C]NNC-112; Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 21 Years to 65 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Solid Tumors
Interventions: AMG 305; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Duarte, California • Hackensack, New Jersey • New York, New York + 3 more

Conditions: Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma, Renal Cell Carcinoma (RCC)
Interventions: VSV-IFNβ-NIS, Pembrolizumab, ipilimumab + nivolumab; Biological
Lead sponsor: Vyriad, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Rochester, Minnesota • Cleveland, Ohio

Conditions: Breast Cancer
Interventions: GDC-0927; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Germantown, Tennessee + 1 more

Conditions: Healthy Volunteers, Autoimmune Disease
Interventions: LAD191, Placebo; Drug · Other
Lead sponsor: Almirall, S.A.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Miami, Florida • Philadelphia, Pennsylvania • San Antonio, Texas

Conditions: Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
Interventions: AFNT-211; Drug
Lead sponsor: Affini-T Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • New Haven, Connecticut • New York, New York + 5 more

Conditions: Locally Advanced Solid Tumor, Metastatic Tumor, Colorectal Adenocarcinoma
Interventions: TST003; Drug
Lead sponsor: Transcenta Therapeutics (Hangzhou) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Portland, Oregon • Dallas, Texas • San Antonio, Texas

Conditions: Age-related Macular Degeneration
Interventions: QA102, Placebo; Drug
Lead sponsor: Smilebiotek Zhuhai Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Knee Osteoarthritis, Knee Osteoarthritis (Knee OA), Knee Osteoarthritis (OA)
Interventions: Registry (N/A); Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cardiac Arrhythmias, Electroanatomic Mapping, Cardiac Ablation
Interventions: Rhythmia Mapping System; Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
Interventions: Bomedemstat, Venetoclax; Drug
Lead sponsor: Terrence J Bradley, MD; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV
Interventions: Emtricitabine and tenofovir disoproxil fumarate; Drug
Lead sponsor: Philadelphia Fight; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Malaria
Interventions: VRC-MALMAB0100-00-AB, Plasmodium falciparum (P. falciparum) sporozoite challenge; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Baltimore, Maryland • Bethesda, Maryland

Conditions: Central Nervous System Neoplasms, Neoplasm Metastasis
Interventions: Temozolomide; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Solid Tumors
Interventions: BMS-986416, Nivolumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Atlanta, Georgia • Baltimore, Maryland • Hackensack, New Jersey + 3 more

Conditions: Chronic Kidney Diseases
Interventions: Program A, Program B; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 75 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Brockport, New York • Canandaigua, New York • Hornell, New York + 1 more

Conditions: Hemophilia B
Interventions: IB1001, nonacog alfa; Biological
Lead sponsor: Medexus Pharma, Inc.; Industry
Eligibility: 5 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 10
States / cities: Duarte, California • Los Angeles, California • Atlanta, Georgia + 7 more

Conditions: Urothelial Cancer, Bladder Cancer
Interventions: Dato-DXd, Carboplatin, Cisplatin, Gemcitabine; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 38
States / cities: Fullerton, California • Glendale, California • La Jolla, California + 34 more

Conditions: Solid Tumors
Interventions: ARQ 761, ARQ 761 Weekly Administration, Bi-Weekly Administration of ARQ 761, Two Consecutive Weeks Administration of ARQ 761 with one week of rest; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Melanoma, Merkel Cell Carcinoma, Skin Squamous Cell Carcinoma, Microsatellite Instability High, Triple Negative Breast Cancer, Mesothelioma, Thymic Cancer, Cervical Cancer, Biliary Tract Cancer, Hepatocellular Carcinoma, Ovarian Cancer, Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Anal Cancer
Interventions: Nanrilkefusp alfa, Pembrolizumab; Drug
Lead sponsor: SOTIO Biotech AG; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: New Haven, Connecticut • Pittsburgh, Pennsylvania • Houston, Texas

Conditions: Colon Cancer Metastatic, Head and Neck Cancer Metastatic, Metastatic Non-Small Cell Lung Cancer, Urothelial Carcinoma, Metastatic Melanoma
Interventions: ADXS-NEO, Pembrolizumab; Biological
Lead sponsor: Advaxis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 5
States / cities: Scottsdale, Arizona • Los Angeles, California • New Orleans, Louisiana + 2 more

Conditions: Alpha-1 Antitrypsin Deficiency, AATD
Interventions: INBRX-101/rhAAT-Fc; Drug
Lead sponsor: Inhibrx Biosciences, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Sacramento, California • Gainesville, Florida • Miami, Florida + 2 more

Conditions: Healthy Volunteers
Interventions: FTX-101, Placebo; Drug
Lead sponsor: Find Therapeutics; Industry
Eligibility: 18 Years to 59 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Breast Cancer
Interventions: IPI-504; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Boca Raton, Florida • Lake Worth, Florida + 3 more

Search by objective public record fields.

Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)

Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors

QA102 Phase 1 Study in Healthy Young and Older Adult Subjects

Creation of a Prospective Data Collecting Registry for Genicular Artery Embolization for Arthritis

Clinical Utility and Validation of the Rhythmia Mapping System for the Treatment of Cardiac Arrhythmias

Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

PrEP With TDF/FTC to Prevent HIV-1 Acquisition in Young MSM and Transgender Women of Color

Trial to Evaluate CIS43LS in Healthy Adults

Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy

A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors

Chronic Kidney Disease-Education (CKD-EDU)

Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Clinical Trial of ARQ 761 in Advanced Solid Tumors

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency

SAD and MAD Study of FTX-101 in Healthy Male Subjects

A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer